DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial ...

Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and ...

DURHAM, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial ...

Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no ...

– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was ...

DURHAM, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...

Pediatric vascular trauma, although infrequent, represents a significant clinical challenge due to the unique physiological and developmental characteristics of children. Such injuries range from ...

Getty Images It is imperative to consider the potential life-saving benefits of IVC ligation despite the higher incidence of associated complications. In the largest multicenter study of factors ...